Latest news with #MAA
Pink Villa
a day ago
- Entertainment
- Pink Villa
MAA Ending Explained: Who is the real villain in Kajol's supernatural drama and does post-credit scene hint at Shaitaan 2?
Disclaimer: This article contains spoilers. MAA, starring Kajol in the lead, is now running in cinemas. The Vishal Furia-directed movie blends horror with mythology, exploring the ultimate battle between Goddess Kali and the demon Raktabeej. Although the climax of MAA follows the typical ending of triumph over evil, the way it is shot and presented makes it a chilling experience for the audience. Still, if you are confused about the climax and couldn't understand how the last act unfolded and whether it is connected to Shaitaan 2, then keep scrolling further. Maa movie ending explained: Who is the real villain? The climax of Maa shows Ambika (played by Kajol) trying to return to Kolkata from her village with her daughter Shweta, after a demon attempts to abduct her. However, she couldn't succeed as the evil forces attacked her and threw her out of the car, resulting in Shweta getting abducted. Furthermore, Ambika found herself in a hut belonging to an old woman, who was regarded as a witch with a 40-year-old history. The old woman further narrates a story to Ambika and tells her how she was ostracized. She also revealed the man behind all conspiracies and evil practices in the village and he is none other than Joy Dada (played by Ronit Roy). The old woman revealed that it was Joy who sacrificed the baby to the demon and then r*ped her. He was the one who influenced people to believe that the woman was a witch, as she was against sacrificing the girl child when she performed Kali Puja. Meanwhile, cops confront Joy Dada (demon), who admitted to murdering Shuvankar (Ambika's husband) and his own father to make sure Ambika and Shweta return to the village, so that he can fulfil his sinister intent of impregnating Shweta's womb. Joy Dada mentioned that he was confronted by the demon Raktabeej who had asked him to bring the next girl child of his family when she hits puberty so that he can put Raktabeej inside her. How does Ambika fight the demon? Did Shweta get impregnated? At her ancestral home, Ambika performs the Kali Puja and takes the blessings of the divine power to triumph over evil. She further heads towards the haunted forest only to be killed brutally by the demon. Thankfully, she is reborn with divine powers of Maa Kali and achieves a victory over evil by taking out his heart. Meanwhile, Ambika's daughter Shweta gets impregnated by the devil, which forces Ambika to sacrifice her own daughter for the sake of the people. When she was about to behead her daughter, all the souls of earlier sacrificed girl children appeared. Meanwhile, the old woman stops Ambika and reveals that the prophecies of Maa Kali were misinterpreted, and the Goddess has reversed the Demon's raktabeej from Shweta's womb. Does the post-credit scene of Maa hint at Shaitaan 2? In the post-credit scene, a man wearing a hoodie (played by R Madhavan) enters the haunted forest with the background song of Shaitaan. He then collects the ashes of the demon in one hand and turns himself into a demon. Hinting at Shaitaan 2, Madhavan's character Vanaraj says, 'Tum insaano ki sbse badi bewakoofi pta hai kya hai? Tumhe lagta hai tumne bure ko maar kar burai ko maar diya, mujhe maar diya. Lekin jab tak iss Brahmand me insan zinda rahega, tab tak uske andar ka Shaitaan zinda rahega.' Vanraj laughs and the credits start rolling.
Business Wire
a day ago
- Business
- Business Wire
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients and a well-matched external control group. Collectively, the results demonstrate a 61% response rate and, compared to the matched external control, a three-fold improvement in overall survival. The submission also includes outcomes in over 130 TA-TMA patients treated with narsoplimab under Omeros' expanded access program. Narsoplimab has been granted orphan drug designation by the EMA for treatment in hematopoietic stem cell transplant, enabling review of the MAA through the centralized procedure. This allows for a single marketing authorization to cover all EU member states and the European Economic Area countries of Iceland, Liechtenstein and Norway. The review procedure begins in mid-July and will follow a standard review timeline. The Committee for Medicinal Products for Human Use (CHMP) will conduct the scientific assessment and will issue an opinion at the end of the review. This opinion is typically adopted by the European Commission, with a final decision expected in mid-2026. The MAA submission follows the acceptance for review by the U.S. Food and Drug Administration (FDA) of the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of TA-TMA. The resubmission was assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025. About Narsoplimab Narsoplimab, also known as 'OMS721,' is an investigational fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 has been demonstrated to leave intact the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. A biologics license application (BLA) for use of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is under review by the U.S. Food and Drug Administration (FDA) and Omeros has submitted the corresponding European MAA. FDA has granted narsoplimab breakthrough therapy and orphan drug designations for TA-TMA and orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in hematopoietic stem-cell transplant. About Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a significant and often lethal complication of stem cell transplantation. This condition is a systemic, multifactorial disorder caused by endothelial cell damage induced by conditioning regimens, immunosuppressant therapies, infection, graft-versus-host disease, and other factors associated with stem cell transplantation. Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of TA-TMA. The condition occurs in both autologous and allogeneic transplants but is more common in the allogeneic population. In the United States and Europe, approximately 30,000 allogeneic transplants are performed annually. Recent reports in both adult and pediatric allogeneic stem cell transplant populations have found an approximately 40-percent incidence of TA-TMA, and high-risk features may be present in up to 80 percent of these patients. In severe cases of TA-TMA, mortality can exceed 90 percent and, even in those who survive, long-term renal sequalae (e.g., dialysis) are common. There is no approved therapy or standard of care for TA-TMA. About Omeros Corporation Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in clinical development for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the 'safe harbor' created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'likely,' 'look forward to,' 'may,' 'objective,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'slate,' 'target,' 'will,' 'would' and similar expressions and variations thereof. Forward-looking statements, including statements regarding the anticipated review process and timing of FDA action on the resubmitted BLA for narsoplimab in the United States, the anticipated review process and timing of EMA action on the MAA submission, the prospects for obtaining FDA or EMA approval of narsoplimab in any indication, and expectations regarding the sufficiency and availability of our capital resources to fund current and planned operations, including the potential commercialization of narsoplimab if it is approved by FDA or the EMA, are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unfavorable or unexpected regulatory conclusions or interpretations related to the clinical data, external registry data, statistical analyses or other information and data included in the narsoplimab BLA or narsoplimab MAA, inability to respond satisfactorily to information requests during regulatory review of the narsoplimab BLA or MAA, potential differences between the diagnostic criteria used in our pivotal trial and in the external registry, and whether FDA and the EMA determine the registry used in our statistical analysis is sufficiently representative of TA-TMA patients, unanticipated or unexpected outcomes or requirements of regulatory processes in relevant jurisdictions, our financial condition and results of operations, including our ability to raise additional capital for our operations on favorable terms or at all, regulatory processes and oversight, challenges associated with manufacture or supply of our products to support clinical trials, regulatory inspections and/or commercial sale following any marketing approval, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading 'Risk Factors' in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2025 and in subsequent reports filed with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
India.com
a day ago
- Entertainment
- India.com
Maa Twitter Review: Netizens call Kajol's horror debut ‘Flawed yet…'
Maa Twitter Review: Directed by Vishal Furia, Maa marks Kajol's powerful return to the big screen, her first full‑blown horror in her career, and she delivers. It's intense, gripping, and unlike any typical Bollywood fare. The film, which hit cinemas today, June 27th, revolves around a mythological horror rooted in maternal courage and this mother's battle with a powerful curse will keep you hooked till the end. Backed by Ajay Devgn's production house, Maa is expected to make a strong impact at the box office. Early estimates suggest that the film could collect anywhere between Rs 4.5 crore to Rs 6.5 crore on its opening day. The makers are hopeful that Kajol's Ma will surpass the Day 1 earnings of Shahid Kapoor's Deva , which had opened with Rs 5.78 crore. Check Twitter Reviews on Maa After watching the film, one of the users wrote, ' Strong performance! It delivers on atmosphere and emotion, but loses pace in the first hour and feels longer than needed. While the visual effects work in parts, some scenes lack polish. The connection to the Shaitaanverse feels underdeveloped.' Strong performance! It delivers on atmosphere and emotion, but loses pace in the first hour and feels longer than needed. While the visual effects work in parts, some scenes lack polish. The connection to the Shaitaanverse feels underdeveloped.#MaaReview — Shiwani Dayal (@ShiwaniK1) June 27, 2025 '#MAA is a mythological horror film which was mostly undetailed and illogical… Plot was decent(fairytale fantasy), but execution falters … Bgm was good… The movie has lots of VFX shots, which were actually good and clear… The cast did well…But overall, it is neither as good as #Shaitaan nor like #Streeverse films… In the two twists, one was expected, and one was not… Backstory misses the detailing as Furia did in his previous outing #Chhorri2 too … Attacking/face off scenes could have been composed better … Overall an average fare for me … Wait for OTT.' #MAA is a mythological horror film which was mostly undetailed and illogical… Plot was decent(fairytale fantasy) , but execution falters … Bgm was good… Movie has lots of VFX shots which were actually good and clear… Cast did well…But overall, it is neither good as… — . (@muralistweetz2) June 27, 2025 Another user wrote, '#MaaReview: Kajol shines in this gripping mythological horror! Vishal Furia crafts a chilling tale of a mother's fierce love vs dark forces. Strong VFX, tight 2h13m runtime. A must-watch for horror fans!' Another user wrote, '#Maa is simply terrific stuff. A paranormal subject layered with emotions. The film is a must-watch for the brilliance of #Kajol and the VFX and BGM. #ronitboseroy #IndraneilSengupta are equally competent. Brilliant.' #MaaReview#Kajol shines in a gripping horror! Emotions + scares = perfect blend 💥 ⭐️⭐️⭐️½ | #Maa is not just horror, it's heart!#OneWordReview: GRIPPING 🔥#VishalFuria #RonitBoseRoy
Time of India
a day ago
- Entertainment
- Time of India
'Maa' reviews out: Netizens hail Kajol's brilliant performance, praise VFX
Kajol's supernatural drama 'Maa' hit the big screens on Friday. Fans who watched the early shows of the horror mythological film in theatres, have now shared their reviews of the Kajol starrer. As expected, the veteran actress has stolen the show with her poignant performance as a desperate mother who races against time to save her child from evil supernatural forces. 'All I can say today is that I am mesmerized by @itsKajolD in #MAA. She carries the film on her shoulders. Kajol is the most powerful actress in India today who can breathe fire into a scene with just a look or expression. And her eyes emote. Kajol is BRILLIANT in & as Maa..' wrote one fan on X. — upalakbr999 (@upalakbr999) Another praised the movie for its strong emotional core and brilliant visual effects. Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track default , selected Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Live the Luxe Life – 3 BHK at ₹3.85 Cr* | Sunteck City Sunteck City Learn More Undo — ahmy30 (@ahmy30) Another tweeted, 'Yesterday saw the film MAA starring Kajol Devgan. Should say excellent film, excellent direction, excellent music, and what a wonderful performance from Kajol!' — BabbuJMehra (@BabbuJMehra) However, not all reviewers were impressed. One called out the movie for having a tedious plot and being unintentionally hilarious. ''Maa Kasam,' what a squandering of talents on a plot that's lethargic, uninspiring, and triggers unintentional laughs rather than shivers,' the comment read. — cineblues (@cineblues) Inside The World Of Maa Helmed by filmmaker Vishal Furia, Maa is a spine-chilling blend of mythology and horror, led by Kajol in a commanding central role. Alongside her, the cast includes Ronit Roy, Indraneil Sengupta, and Kherin Sharma, all playing pivotal characters who help shape this dark, emotionally charged narrative. The storyline follows a devoted mother—portrayed by Kajol—who sets out on a seemingly ordinary road journey with her daughter. However, the path soon twists into a nightmarish ordeal as they encounter spectral entities and unearthly forces. At the core of this haunting tale lies a mysterious, cursed tree and an age-old legend shrouded in blood and fear. As the horrors unfold, Kajol's character is forced to confront ancient evils that threaten to consume not just her but the bond she shares with her daughter. Drawing creative energy from the mythological saga of Goddess Kali and the fearsome demon Raktabija, the film channels deep-rooted cultural lore into a terrifying cinematic experience. The visual tone and narrative pacing invoke the wrath and power of divine feminine energy clashing against demonic darkness, giving the story both emotional gravity and mythic grandeur. Maa is the second chapter in Ajay Devgn's evolving horror cinematic universe, coming on the heels of the well-received Shaitaan. With Kajol stepping into a fiery, protective mother's role—unafraid to face down malevolent spirits—the film builds on themes of maternal strength, sacrifice, and otherworldly terror. With its eerie atmosphere, emotionally charged storytelling , and myth-inspired villainy, Maa positions itself as a compelling and intense addition to the supernatural horror genre, continuing Ajay Devgn's ambitious exploration of fear, folklore, and family.
India.com
a day ago
- Entertainment
- India.com
MAA Movie Review: A Mythological Horror Powered by Kajol's Unforgettable Performance
Director: Vishal Furia Cast: Kajol, Ronit Roy, Indraneil Sengupta, Kherin Sharma, Jitin Gulati, Gopal Singh, Surjyasikha Das, Yaaneea Bharadwaj, Roopkatha Chakraborty Runtime: 135 minutes Rating: 4/5 Departing from his last action thriller, Vishal Furia, tackles a fresh and new genre, mythological-horror, tells a tale rooted in cultural folklore. Instead of relying on gimmicks, it blends emotion, and dread into a layered mythical narrative. Taking inspiration from folklore, packing it with powerhouse performances, hence creating a mythological horror entertainer that channels maternal grief into something mythic and terrifying. Set in the cursed village of Chandrapur, MAA begins as a personal loss and slowly turns into a spiritual war. It narrates a raw and immersive tale, what happens when a mother's mourning collides with a curse, that to be a Daitya, born from spilled demonic blood, still alive and hungry and hunting. The film is a modern take on Kali Vs Raktabeej, from this seed of legend, the filmmaker builds a mysterious world which is terrifying and yet relatable. The film delves into Faith Vs Evil, it's the main element of the narrative, where mythology and belief clash with dark forces in a modern-day setting. The film creatively reimagines the ancient tale of Kali and Raktabeej, infusing it with a contemporary tale. The epic climax of the film which is visceral, powerful, and crafted for the big screen is an ode to the mythology legend. Kajol as Ambika, delivers one of the career best performance.. Her multi-layered and nuances performance ranging from a grieving widow to a fiercely protective mother, is outstanding. Ambika is probably Kajol's most daring and finest performance yet — a fearless, mythic role that fuses emotional depth with the power of divine fury. It's not just a mother defending her child against an evil — it's maternal love which turns into a godlike force of protection and vengeance. Ambika's daughter Shweta (Kherin Sharma) becomes the target of family curse, and Ambika with the help of divine intervention becomes something more than a mother, she is the force to reckon with. Ronit Roy as Joy Dev, the Sarpanch of the village, the ever so helping and understanding induvial, bring subtlety and shock, a rare combo for an actor, and his role is such an enigmatic character, the you're glued to his presence. Indraneil Sengupta appears briefly but memorably, grounding the story in tragedy before it spirals into horror. The amazing ensemble — including Gopal Singh, Yaaneea Bharadwaj, Jitin Gulati, and Roopkatha Chakraborty — breathe life into the cursed village, portraying a community paralyzed by fear yet complicit in silence. These are not crowd characters; each feels like a person with something to offer. Vishal Furia handles the subject with confidence, infuses mythology, horror and drama with right amount of emotions and thrills, the entire narrative is beating pulse which is rhythmic and just. His horror is transitional, symbolic, and laced with folklore. The Daitya is never just a monster; but its embodied with fear and sins. The film's mythology-driven suspense keeps viewers on edge from start to finish, it's an emotionally spine-chilling ride that doesn't just spook, but makes you feel eerie. The film is visually stunning. The cinematography captures the haunting beauty of unexplored rural India — dilatating buildings, ancient temples, dense and misty forests, the bottomless darkness of long night — making Chandrapur feel like a living, breathing organism. The super-fine VFX and special effects are impressive, they take the narrative forward. A special shout-out to, The Kali Shakti song, which particularly stands out as a spiritual and divine high point — an audio-visual spectacle that bridges myth with modernity and sends chills down the spine. MAA is a story of a woman pushed to the brink, not just by demons or by loss, it's about what happens when a mother stops asking for help and becomes the help, its empowering.
